Laddar...
Safety and Efficacy of Rivastigmine in Adolescents with Down Syndrome: Long-Term Follow-Up
Following the completion of a 20-week, open-label study of the safety and efficacy of liquid rivastigmine for adolescents with Down syndrome, 5 of the 10 adolescents in the clinical trial continued long-term rivastigmine therapy and 5 did not. After an average period of 38 months, all 10 subjects re...
Sparad:
| Huvudupphovsmän: | , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Mary Ann Liebert, Inc.
2010
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3025176/ https://ncbi.nlm.nih.gov/pubmed/21186971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2009.0099 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|